UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu Sciences has launched a preclinical development program for its B.R.E.A.S.T.™ 3D-printed bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine (WFIRM). The study will evaluate the durability, host tissue integration, and resorbability of the proprietary CXU™ matrix, leveraging WFIRM’s advanced bioprinting infrastructure.
Key figures
- Drug Name
- B.R.E.A.S.T.™
- Phase Of Trial
- Preclinical
- Regulatory submission target
- early 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.